FDA Clears VNS Device for Paroxysmal Hemicrania, Hemicrania Continua
Patients treated with gammaCore experienced clinically meaningful benefits.
Neurology
Vagus Nerve Stimulation System Approved for Post Stroke Rehabilitation Therapy
The Vivistim System features an implantable pulse generator, which is placed just under the skin in the chest of the patient, and a lead wire.
Nurtec ODT Approval Expanded to Include Migraine Prevention
Rimegepant is an oral calcitonin gene-related peptide receptor antagonist.
Guidelines Developed for Diagnosing, Treating Botulism
Signs and symptoms of some neurologic conditions overlap with botulism; thorough, serial neurologic exams should be conducted.
Combination Treatment Appears Beneficial for Chronic Migraine
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
Hizentra Dosing Guidelines Updated to Reflect New Study Findings
Hizentra is indicated for the treatment of adult patients with CIDP as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
FDA Clears Novel Device for Upper Extremity Rehabilitation After Stroke
The device is available only with a prescription and may be used as part of rehabilitation therapy.
Nulibry Now Available for Molybdenum Cofactor Deficiency Type A
MoCD Type A is a rare, inborn error of metabolism caused by mutations in the MOCS1 gene that results in toxic sulfite accumulation in the brain.
FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
The sNDA submission was supported by data from the pivotal phase 3 HARMONY study.
Nulibry Approved for Molybdenum Cofactor Deficiency Type A
Nulibry replaces missing cyclic pyranopterin monophosphate, which is needed to reduce levels of neurotoxic sulfites.
